HealthLinx and InSymbiosis to co-develop therapeutic for lung disease
23-Jun-2008 -
HealthLinx Limited and InSymbiosis Discovery Inc have signed a Letter of Intent to co-develop HTX's peptide therapeutic CR014 and related compounds for applications in Acute Respiratory Distress Syndrome (ARDS) and Acute Lung Injury. The companies will proceed under a joint venture agreement ...
clinical trials
inflammation
joint ventures
+3